Xention Limited

Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Healthcare Aktiengesellschaft

Noriyuki Yamamoto

Muneto Mogi

Masaomi Tajimi

Takeshi Yura

Hiroshi Fujishima

Klaus Urbahns

Nagahiro Yoshida

Yasuhiro Tsukimi

Toshiya Moriwaki

Tsutomu Masuda

Toshio Kokubo

Masahiro Shiroo

Klemens Lustig

Josef Pernerstorfer

Heinrich Meier

Nicole Diedrichs

Achim Hermann

William Johnston Scott

Martha E Rodriguez

Margaret Ann Popp

Jean De Vry

Ming Wang

Hiroshi Komura

Yingfu Li

Scott Miller

Timothy Lowinger

Axel Bouchon

Arnel B Concepcion

Makiko Marumo

Hiroko Yoshino

Norihiro Kawamura

Aniko M Redmann

Gyoonhee Han

Fumihiko Hayashi

Jang Gupta

Hiroaki Yuasa

Elke Reissmuller

Elke Reiβmüller

Elke Reissmüller

Masaomi 1-8-17 Sakuragaoka Seika-Cho Tajimi

This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

Tetrahydro-naphthalene derivatives

This invention relates to tetrahydro-Naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tethrahydro&#x2014;Naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontienence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

Tetrahydro-quinolinylurea derivatives

This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q, Q, Qand Qare defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q, Q, Q, Q, Q, R, na, ma, Xand Rare defined.

Tetrahydro-naphthalene and urea derivatives

This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD.

Hydroxy tetrahydro-naphthalenylurea derivatives

This invention relates to tetrahydro-naphthalene derivatives of formula (I) in which the variable groups are as defined in the specification and claims, and tautomeric and stereoisomeric forms and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. The compounds, pharmaceutical compositions containing them, and methods of treatment using them are disclosed and claimed.

Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists

This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excellent activity as VR1 antagonist and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

Hydroxy-tetrahydro-naphthalenylurea derivatives

This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I) in which Rrepresents hydrogen or Calkyl, and X represents &#x2014;N(H)Y, &#x2014;(H)&#x2014;CalkyleneY, biphenyl or Calkyl substituted by biphenyl, and the group Yis an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

A compound of the formula (I)in which Ris &#x2014;OR, &#x2014;SR, &#x2014;SOR, &#x2014;SOR, &#x2014;NHR, or &#x2014;NRR, and R, R, and Rare as defined broadly in the text. Ris H, C-Calkyl, carbamoyl, or an ester group. Ris thienyl, pyridyl optionally substituted by halogen or C-Calkoxy; naphthyl optionally substituted by C-Calkoxy; dioxane fused phenyl; dioxacyclopentane fused phenyl; or optionally substituted phenyl. Y is CH or N. A process for preparing such compounds, pharmaceutical compositions containing such compounds, and a method of treating asthma using them are also disclosed and claimed.

Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Growing community of inventors

Osaka-fu, Japan

Noriyuki Yamamoto